Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · IEX Real-Time Price · USD
3.355
+0.065 (1.98%)
Jul 22, 2024, 10:28 AM EDT - Market open
Tenax Therapeutics Employees
As of December 31, 2023, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,683,792
Market Cap
6.57M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Telesis Bio | 147 |
| Sunshine Biopharma | 44 |
| ReShape Lifesciences | 29 |
| Notable Labs | 16 |
| Virios Therapeutics | 4 |
| Cadrenal Therapeutics | 4 |
| Xenetic Biosciences | 4 |
| Alaunos Therapeutics | 1 |
TENX News
- 2 months ago - Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - GlobeNewsWire
- 3 months ago - Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” - GlobeNewsWire
- 4 months ago - Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results - GlobeNewsWire
- 4 months ago - Tenax Therapeutics to Present at the 36th Annual Roth Conference - GlobeNewsWire
- 5 months ago - Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 - GlobeNewsWire
- 5 months ago - Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan - GlobeNewsWire
- 5 months ago - Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering - GlobeNewsWire